Exact Sciences Stock Today
| EXAS Stock | USD 44.92 0.26 0.58% |
PerformanceVery Weak
| Odds Of DistressBelow Average
|
EXACT Sciences is selling for under 44.92 as of the 19th of March 2025; that is 0.58% down since the beginning of the trading day. The stock's lowest day price was 43.75. EXACT Sciences has about a 41 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Note, on November 20, 2020, Representative Jim Hagedorn of US Congress acquired under $15k worth of EXACT Sciences's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 1st of February 2001 | Category Healthcare | Classification Health Care |
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin. Exact Sciences operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. The company has 185.76 M outstanding shares of which 10.21 M shares are currently shorted by private and institutional investors with about 5.07 trading days to cover. More on EXACT Sciences
Moving together with EXACT Stock
Moving against EXACT Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
EXACT Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman | Kevin Conroy | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, ARCA Biotechnology, NASDAQ Composite, NASDAQ Health Care, NASDAQ Composite Total, Health Care, Biotechnology, Diagnostics & Research, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsEXACT Sciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand EXACT Sciences' financial leverage. It provides some insight into what part of EXACT Sciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EXACT Sciences (EXAS) is traded on NASDAQ Exchange in USA. It is located in 5505 Endeavor Lane, Madison, WI, United States, 53719 and employs 6,900 people. EXACT Sciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 8.39 B. EXACT Sciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 185.76 M outstanding shares of which 10.21 M shares are currently shorted by private and institutional investors with about 5.07 trading days to cover.
EXACT Sciences currently holds about 728.04 M in cash with 210.54 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.11.
Check EXACT Sciences Probability Of Bankruptcy
Ownership AllocationThe majority of EXACT Sciences outstanding shares are owned by institutions. These other corporate entities are usually referred to as non-private investors looking to obtain positions in EXACT Sciences to benefit from reduced commissions. Thus, outside corporations are subject to a different set of regulations than regular investors in EXACT Sciences. Please pay attention to any change in the institutional holdings of EXACT Sciences as this could imply that something significant has changed or is about to change at the company. On November 20, 2020, Representative Jim Hagedorn of US Congress acquired under $15k worth of EXACT Sciences's common stock.
Check EXACT Ownership Details
EXACT Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| William Blair Investment Management, Llc | 2024-12-31 | 3.4 M | |
| Geode Capital Management, Llc | 2024-12-31 | 3.1 M | |
| Champlain Investment Partners, Llc | 2024-12-31 | 2.4 M | |
| Millennium Management Llc | 2024-12-31 | 2.4 M | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 2.2 M | |
| Artisan Partners Limited Partnership | 2024-12-31 | 2 M | |
| Armistice Capital, Llc | 2024-12-31 | 1.6 M | |
| Spyglass Capital Management Llc | 2024-12-31 | 1.5 M | |
| Ubs Group Ag | 2024-12-31 | 1.5 M | |
| Fmr Inc | 2024-12-31 | 20.8 M | |
| Capital World Investors | 2024-12-31 | 17.5 M |
EXACT Sciences Historical Income Statement
EXACT Stock Against Markets
EXACT Sciences Corporate Management
| James Herriott | General VP | Profile | |
| Jeffrey CFA | Chief Officer | Profile | |
| Ana Hooker | Chief Officer | Profile | |
| Aaron Bloomer | Executive Finance | Profile | |
| Vic Parker | Head Sales | Profile | |
| Sarah Condella | Executive Resources | Profile |
Additional Tools for EXACT Stock Analysis
When running EXACT Sciences' price analysis, check to measure EXACT Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy EXACT Sciences is operating at the current time. Most of EXACT Sciences' value examination focuses on studying past and present price action to predict the probability of EXACT Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move EXACT Sciences' price. Additionally, you may evaluate how the addition of EXACT Sciences to your portfolios can decrease your overall portfolio volatility.